Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients

OncoImmunology

Volumn 2, Issue 9, 2013, Pages

  Raja, Karthick Raja Muthu ^a   Hajek, Roman ^a,b,c  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

Author keywords

Disease progression; FoxP3; Immune suppression; Multiple myeloma; Suppressor cells; T regulatory cells

Indexed keywords

ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; DENDRITIC CELL VACCINE; IMMUNOMODULATING AGENT;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE FREE SURVIVAL; HUMAN; IMMUNE DEFICIENCY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MULTIPLE MYELOMA; OVERALL SURVIVAL; REGULATORY T LYMPHOCYTE; SOLID TUMOR; SYMPTOM; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84890285795     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25619     Document Type: Article

References (9)

1. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23:3-9; PMID:18971951; http://dx.doi.org/10.1038/leu.2008.291
2. Muthu Raja KR, Rihova L, Zahradova L, Klincova M, Penka M, Hajek R. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS One 2012; 7:e47077; PMID:23071717; http://dx.doi. org/10.1371/journal.pone.0047077
3. Feyler S, Scott GB, Parrish C, Jarmin S, Evans P, Short M, et al. Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One 2012; 7:e35981; PMID:22666318; http://dx.doi. org/10.1371/journal.pone.0035981
4. Tang XL, Smith TR, Kumar V. Specific control of immunity by regulatory CD8 T cells. Cell Mol Immunol 2005; 2:11-9; PMID:16212906
5. Muthu Raja KR, Kubiczkova L, Rihova L, Piskacek M, Vsianska P, Hezova R, et al. Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment. PLoS One 2012; 7:e49446; PMID:23152910; http://dx.doi.org/10.1371/journal.pone.0049446
6. Muthu Raja KR, Kovarova L, Hajek R. Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. Leuk Lymphoma 2012; 53:1406-8; PMID:22200079; http://dx.doi.org/10.3109/1042819 4.2011.652106
7. Muthu Raja KR, Plasil M, Rihova L, Pelcova J, Adam Z, Hájek R. Flow cytometry based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment. Cytometry Part B: Clinical Cytometry 2013; Forthcoming; http://dx.doi.org/10.1002/cytob.21109
8. Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010; 10:155-67; PMID:20088798; http://dx.doi. org/10.2174/156800910791054239
9. Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, Trapani JA, et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011; 117:1605-13; PMID:20978269; http://dx.doi. org/10.1182/blood-2010-04-278432